Lilly to stop development of lymphoma drug enzastaurin

05/12/2013 | Genetic Engineering & Biotechnology News

Eli Lilly & Co. said it would stop developing the experimental drug enzastaurin as a treatment for diffuse large B-cell lymphoma after obtaining unfavorable results from a late-stage trial. The drug failed to significantly improve disease-free survival against placebo in patients at high risk of relapse after chemotherapy.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel
Cardinal Health
Columbus, OH
Regulatory Affairs Specialist
Stryker
Mahwah, NJ
Sr. Principal OptoMechanical Engineer - 14000008M2
Abbott
San Jose, CA
Sr. Principal Electrical Engineer - 14000008LR
Abbott
San Jose, CA
Senior Director Medical Affairs
Edwards Lifesciences
Irvine, CA